ライフサイエンスコーパス: bacterial vaginosis

1 la vaginalis (one of the causative agents of bacterial vaginosis).

2 althy microbiota, 4-6 intermediate, and 7-10 bacterial vaginosis).

3 need for new treatments to prevent recurrent bacterial vaginosis.

4 ty to sexually transmitted infections during bacterial vaginosis.

5 antimicrobial agent used in the treatment of bacterial vaginosis.

6 diate Nugent scores but not among women with bacterial vaginosis.

7 Gardnerella vaginalis predominates in bacterial vaginosis.

8 ic STIs, compared with women with no STIs or bacterial vaginosis.

9 esized to play a role in the pathogenesis of bacterial vaginosis.

10 ch are used as a factor for the diagnosis of bacterial vaginosis.

11 response to vaginal symptoms associated with bacterial vaginosis.

12 y visits, 40.2% were classified as involving bacterial vaginosis.

13 tcome data in women who are asymptomatic for bacterial vaginosis.

14 in 3 months before enrollment, 131 (39%) had bacterial vaginosis.

15 and treating asymptomatic pregnant women for bacterial vaginosis.

16 or average-risk pregnancies for asymptomatic bacterial vaginosis.

17 microbiological constituents responsible for bacterial vaginosis.

18 ne were associated with an increased risk of bacterial vaginosis.

19 lammatory-cytokine expression in response to bacterial vaginosis.

20 V-05 (Lactin-V) to prevent the recurrence of bacterial vaginosis.

21 O(2)-producing lactobacilli among women with bacterial vaginosis.

22 ridiales order that were highly specific for bacterial vaginosis.

23 smitted-disease acquisition among women with bacterial vaginosis.

24 and, in females, incident trichomoniasis and bacterial vaginosis.

25 elopment as a probiotic for the treatment of bacterial vaginosis.

26 a vulvovaginitis, Trichomonas vaginitis, and bacterial vaginosis.

27 ffect of N-9 use on vaginal lactobacilli and bacterial vaginosis.

28 rt of ongoing studies on the pathogenesis of bacterial vaginosis.

29 immunodeficiency virus (HIV), and 21.4% had Bacterial vaginosis.

30 pendent of elevated genital inflammation and bacterial vaginosis.

31 le containers, for the pH-based diagnosis of bacterial vaginosis.

32 associated with presumed bacterial agents of Bacterial vaginosis.

33 lies to pregnant persons without symptoms of bacterial vaginosis.

34 tion: ovarian cancer (4 studies; n = 26432), bacterial vaginosis (2 studies; n = 930), trichomoniasis

35 , T vaginalis, 17.8% (12.4%-23.1%; n = 822), bacterial vaginosis, 37.6% (18.0%-57.2%; n = 1208), peri

36 T vaginalis, 29.1% (20.9%-37.2%; n = 5502), bacterial vaginosis, 50.8% (43.3%-58.4%; n = 4280), peri

37 Bacterial vaginosis, a common disorder among young women

38 ne interleukin-8 (IL-8) was not increased in bacterial vaginosis, accounting for low concentrations o

39 Bacterial vaginosis affects 15 to 50% of women of reprod

40 Bacterial vaginosis affects millions of women and is ass

41 Bacterial vaginosis affects one third of reproductive-ag

42 Women with bacterial vaginosis alone or with concurrent Candida spp

43 The prevalence of bacterial vaginosis among lesbians is high.

44 In the US, reported prevalence of bacterial vaginosis among pregnant women ranges from 5.8

45 lis isolates analyzed, 10 from patients with bacterial vaginosis and 10 from patients without bacteri

46 ectly on vaginal fluid from 27 subjects with bacterial vaginosis and 46 without the condition.

47 re warranted, since prevention strategies of bacterial vaginosis and colonization by certain biotypes

48 ively associated with M. genitalium, whereas bacterial vaginosis and cunnilingus were negatively asso

49 bean, and other black (ACB) women, including bacterial vaginosis and herpes simplex virus type-2 (HSV

50 mong African women with a high prevalence of bacterial vaginosis and high adherence to PrEP, the effi

51 ations of antimicrobial polypeptides in both bacterial vaginosis and in vulvovaginal candidiasis, sug

52 udies found no association between confirmed bacterial vaginosis and MHM (OR: 1.07, 95% CI: 0.52-2.24

53 rapeutics for polymicrobial diseases such as bacterial vaginosis and periodontal disease.

54 Cytologic findings identified women with bacterial vaginosis and revealed that cytolysis of vagin

55 nalis infections, but much higher numbers of bacterial vaginosis and vulvovaginal candidiasis infecti

56 view summarizes our current understanding of bacterial vaginosis and where future research should be

57 years of age who had received a diagnosis of bacterial vaginosis and who had completed a course of va

58 pregnant and 99 nonpregnant women, all with bacterial vaginosis and without concurrent sexually tran

59 onorrhoeae, 16.1% for T vaginalis, 18.1% for bacterial vaginosis, and 8.6% for vulvovaginal candidias

60 tion usage, Trichomonas vaginalis infection, bacterial vaginosis, and incident syphilis infection.

61 , and it reduces HPV, genital ulcer disease, bacterial vaginosis, and trichomoniasis among female par

62 h vaginitis, vaginal discharge, candidiasis, bacterial vaginosis, and trichomoniasis.

63 of the transmitter (i.e., male circumcision, bacterial vaginosis, and use of acyclovir) explained 46%

64 traditionally diagnosed vaginal candidiasis, bacterial vaginosis, and vaginal trichomoniasis using so

65 r C trachomatis, N gonorrhoeae, T vaginalis, bacterial vaginosis, and vulvovaginal candidiasis were t

66 After excluding women with concurrent bacterial vaginosis, another possible cause of vaginal s

67 Abnormal vaginal flora and bacterial vaginosis are associated with amplified risks

68 Currently recommended treatment options for bacterial vaginosis are associated with high rates of re

69 at <35 weeks and 2) body mass index <19.8 or bacterial vaginosis as assessed by Gram stain.

70 obstetrical population who have asymptomatic bacterial vaginosis (as diagnosed on the basis of vagina

71 vide the best evidence to date for a risk of bacterial vaginosis associated with douching.

72 Resistance to clindamycin by bacterial vaginosis-associated anaerobic organisms has a

73 The role of newly defined bacterial vaginosis-associated bacteria (BVAB), which ha

74 are emerging regarding the potential role of bacterial vaginosis-associated bacteria in urethritis, a

75 by Lactobacillus iners or a diverse array of bacterial vaginosis-associated bacteria including Gardne

76 Bacterial vaginosis-associated bacteria were associated

77 elicited by colonization with commensal and bacterial vaginosis-associated bacteria.

78 reatment levels of Lactobacillus relative to bacterial vaginosis-associated bacteria.

79 vel taxa (including increased frequencies of bacterial vaginosis-associated bacterium 1 [BVAB1], BVAB

80 bacterial vaginosis (BV)--Atopobium vaginae, Bacterial Vaginosis-Associated Bacterium 2 (BVAB-2), Gar

81 ve PCR for the presence and concentration of bacterial vaginosis-associated microbes and commensal La

82 0 women (median age 33 years), 357 (24%) had bacterial vaginosis at enrolment.

83 tus) or 2 prevalent bacteria associated with bacterial vaginosis (Atopobium vaginae and Prevotella bi

84 ribed were highly prevalent in subjects with bacterial vaginosis but rare in healthy controls.

85 Bacterial vaginosis (BV) affects almost a quarter of US

86 clinical samples from women with and without bacterial vaginosis (BV) and a human 3-dimensional cervi

87 ntly found a significant association between bacterial vaginosis (BV) and acquisition of sexually tra

88 e of 3 molecular assays for the diagnosis of bacterial vaginosis (BV) and examined the impact of an i

89 We assessed the association between recent bacterial vaginosis (BV) and incident Mycoplasma genital

90 nalis is a bacterial species associated with bacterial vaginosis (BV) and its significant adverse seq

91 ontroversy surrounds the association between bacterial vaginosis (BV) and pelvic inflammatory disease

92 Bacterial vaginosis (BV) and vaginal candidiasis are pro

93 Bacterial vaginosis (BV) and vulvovaginal candidiasis (V

94 en implicated in vaginal infections, notably bacterial vaginosis (BV) and vulvovaginal candidiasis (V

95 Both factors are modulated by bacterial vaginosis (BV) and, to some extent, by Lactoba

96 ith diagnoses for the presence or absence of bacterial vaginosis (BV) and/or symptomatic vulvovaginal

97 V prevalence, sexual behavior, and suspected bacterial vaginosis (BV) as defined by Nugent Gram stain

98 ically described as normal, intermediate, or bacterial vaginosis (BV) as defined by Nugent's criteria

99 We sought to assess the relationship between bacterial vaginosis (BV) assessed by Gram stain and inci

100 udy the pathogenesis and transmissibility of bacterial vaginosis (BV) because it can be diagnosed in

101 of vaginal microbes isolated from women with bacterial vaginosis (BV) before and after therapy, 119 n

102 species have been detected in subjects with bacterial vaginosis (BV) by using broad-range PCR assays

103 Bacterial vaginosis (BV) can cause vaginal dysbiosis tha

104 Bacterial vaginosis (BV) causes genital inflammation and

105 ) infected women have a higher prevalence of bacterial vaginosis (BV) compared to HSV-2-seronegative

106 Women with bacterial vaginosis (BV) display reduced vaginal acidity

107 Women with bacterial vaginosis (BV) have complex communities of ana

108 ith sexually transmitted diseases (STDs) and bacterial vaginosis (BV) have increased rates of cytomeg

109 Bacterial vaginosis (BV) in pregnancy is linked to prete

110 Bacterial vaginosis (BV) is a clinical syndrome presenti

111 Bacterial vaginosis (BV) is a common cause of vaginal di

112 Bacterial vaginosis (BV) is a common cause of vaginal in

113 Bacterial vaginosis (BV) is a common clinical syndrome i

114 Bacterial vaginosis (BV) is a common condition among wom

115 Bacterial vaginosis (BV) is a common condition character

116 Bacterial vaginosis (BV) is a common disorder characteri

117 Bacterial vaginosis (BV) is a common polymicrobial disea

118 Bacterial vaginosis (BV) is a common polymicrobial imbal

119 Bacterial vaginosis (BV) is a common vaginal dysbiosis t

120 Bacterial vaginosis (BV) is a condition associated with

121 Bacterial vaginosis (BV) is a condition marked by high v

122 Bacterial vaginosis (BV) is a dysbiotic condition of the

123 Bacterial vaginosis (BV) is a genital infection that fre

124 Bacterial vaginosis (BV) is a highly prevalent condition

125 Bacterial vaginosis (BV) is a major health problem assoc

126 Bacterial vaginosis (BV) is a perturbation of vaginal fl

127 Bacterial vaginosis (BV) is a polymicrobial imbalance of

128 Bacterial vaginosis (BV) is a vaginal microbiome disorde

129 Bacterial vaginosis (BV) is a well-known risk factor for

130 Bacterial vaginosis (BV) is associated with an increased

131 Bacterial vaginosis (BV) is associated with complication

132 Bacterial vaginosis (BV) is associated with HIV acquisit

133 Bacterial vaginosis (BV) is associated with human immuno

134 Bacterial vaginosis (BV) is associated with increased ri

135 Bacterial vaginosis (BV) is caused by the excessive and

136 Bacterial vaginosis (BV) is characterized by dramatic ch

137 Bacterial vaginosis (BV) is characterized by low abundan

138 Bacterial vaginosis (BV) is characterized by low levels

139 Bacterial vaginosis (BV) is difficult to eradicate due t

140 "gold standard" method for the diagnosis of bacterial vaginosis (BV) is lacking.

141 Bacterial vaginosis (BV) is one of the most common cause

142 Bacterial vaginosis (BV) is the most common cause of vag

143 Bacterial vaginosis (BV) is the most common cause of vag

144 Bacterial vaginosis (BV) is the most common cause of vag

145 Bacterial vaginosis (BV) is the most common gynecologica

146 Bacterial vaginosis (BV) is the most common vaginal infe

147 Bacterial vaginosis (BV) is the most prevalent vaginal c

148 Bacterial vaginosis (BV) is the worldwide leading vagina

149 Bacterial vaginosis (BV) may be common among women who r

150 at specific vaginal bacteria associated with bacterial vaginosis (BV) may increase the risk of advers

151 Bacterial vaginosis (BV) may increase women's susceptibi

152 apillomavirus (HPV) infection is affected by bacterial vaginosis (BV) or Trichomonas vaginalis (TV) i

153 Bacterial vaginosis (BV) recurrence posttreatment is com

154 Bacterial vaginosis (BV) represents shifts in microbiota

155 astidious bacteria have been associated with bacterial vaginosis (BV) using broad-range bacterial PCR

156 e-resistant anaerobe, Atopobium vaginae, and bacterial vaginosis (BV) warrants further investigation.

157 Bacterial vaginosis (BV) was diagnosed by Nugent score,

158 m, Mycoplasma hominis, and Candida albicans; bacterial vaginosis (BV) was identified by clinical crit

159 Bacterial vaginosis (BV) was identified recently as a co

160 During a 2-year follow-up, 50 women acquired bacterial vaginosis (BV), 25 acquired symptomatic vulvov

161 Bacterial vaginosis (BV), a common syndrome characterize

162 Gardnerella vaginalis is abundant in bacterial vaginosis (BV), a condition associated with ad

163 dered a pivotal player in the progression of bacterial vaginosis (BV), a condition associated with se

164 Bacterial vaginosis (BV), a disorder of the female repro

165 Bacterial vaginosis (BV), a disruption of the normal vag

166 Women with bacterial vaginosis (BV), an imbalance of the vaginal mi

167 ween vaginal colonization with lactobacilli, bacterial vaginosis (BV), and acquisition of human immun

168 SW) was performed to determine the burden of bacterial vaginosis (BV), and behavioral factors influen

169 umber of lifetime sexual partners, syphilis, bacterial vaginosis (BV), and vaginal candidiasis.

170 Bacterial vaginosis (BV), characterized by an imbalance

171 or L. jensenii vaginally and/or rectally had bacterial vaginosis (BV), compared with 12 (44%) of 27 f

172 Despite the worldwide prevalence of bacterial vaginosis (BV), its etiology is still unknown.

173 Cervicitis commonly occurs in women with bacterial vaginosis (BV), often without concomitant chla

174 Bacterial vaginosis (BV), primarily attributed to Gardne

175 ies most frequently isolated from women with bacterial vaginosis (BV), produces a cholesterol-depende

176 Following all forms of therapy for bacterial vaginosis (BV), recurrence rates are extremely

177 ghts of the expert technical consultation on bacterial vaginosis (BV), sponsored by the National Inst

178 Bacterial vaginosis (BV), the overgrowth of diverse anae

179 During bacterial vaginosis (BV), there is a loss of vaginal aci

180 The primary end points were bacterial vaginosis (BV), vaginal candidiasis, trichomon

181 Infectious vaginitis due to bacterial vaginosis (BV), vulvovaginal candidiasis (VVC)

182 gh vaginal symptoms are common, diagnosis of bacterial vaginosis (BV), vulvovaginal candidiasis (VVC)

183 with 1 or more vaginal infections, including bacterial vaginosis (BV), vulvovaginal candidiasis (VVC)

184 sed by microscopy and limited to testing for bacterial vaginosis (BV), vulvovaginal candidiasis, and

185 hosted an experts technical consultation on bacterial vaginosis (BV), where data regarding controver

186 ful positive indicators for the diagnosis of bacterial vaginosis (BV)--Atopobium vaginae, Bacterial V

187 ian age 22 years, 10.9% with HIV, 21.4% with Bacterial vaginosis (BV).

188 HIV-negative (HIV(-)) women with or without bacterial vaginosis (BV).

189 inalis is detected in women with and without bacterial vaginosis (BV).

190 ginalis as an important etiological agent in bacterial vaginosis (BV).

191 hemical alterations induced by pregnancy and bacterial vaginosis (BV).

192 t therapeutic approaches to the treatment of bacterial vaginosis (BV).

193 aginalis is the most common species found in bacterial vaginosis (BV).

194 extreme genital inflammation and persistent bacterial vaginosis (BV); this subtype could be predicte

195 avaginalis test were compared with a unified bacterial-vaginosis (BV) reference standard incorporatin

196 primary or recurrent genital herpes, having bacterial vaginosis by Nugent criteria, and having had t

197 intention-to-treat population, recurrence of bacterial vaginosis by week 12 occurred in 46 participan

198 percentage of women who had a recurrence of bacterial vaginosis by week 12.

199 ivity (100%) but a low specificity (zero for bacterial vaginosis, candida, and Trichomonas vaginalis)

200 Samples for detection of bacterial vaginosis, Chlamydia trachomatis, and Neisseri

201 he cervix is enhanced in pregnant women with bacterial vaginosis, compared with that in nonpregnant w

202 Bacterial vaginosis during pregnancy has been associated

203 that racial differences persist for rates of bacterial vaginosis even when other known risk factors a

204 ferences and why some but not all women with bacterial vaginosis experience complications.

205 PCR was used to survey bacterial vaginosis flora before and after metronidazole

206 Bacterial vaginosis frequently persists after treatment.

207 ostic tests are available that differentiate bacterial vaginosis from other types of vaginal disorder

208 viral concentrations, menstrual cycle phase, bacterial vaginosis, genital bleeding, or plasma virus d

209 the follow-up prevalences of trichomoniasis, bacterial vaginosis, gonorrhoea, and chlamydia infection

210 Among women with bacterial vaginosis, H(2)O(2)-producing lactobacillus co

211 Women without bacterial vaginosis had 1 to 6 vaginal bacterial species

212 Women with bacterial vaginosis had greater bacterial diversity (P<0

213 While bacterial vaginosis has been associated with an increase

214 Bacterial vaginosis has been associated with preterm bir

215 e rapid point-of-care diagnostic testing for bacterial vaginosis has emerged.

216 eria gonorrhoeae, Trichomonas vaginalis, and bacterial vaginosis have been associated with adverse ma

217 Women with bacterial vaginosis have complex vaginal infections with

218 Women with bacterial vaginosis have different microbiological profi

219 fficacy 62.72% [95% CI -66.59 to 91.66]), or bacterial vaginosis (HIV incidence 0.9 per 100 person-ye

220 or individual physical examination findings (bacterial vaginosis, homogeneous discharge: sensitivity

221 ere baseline chlamydial infection (HR, 5.2), bacterial vaginosis (HR, 2.1), and the occurrence of gen

222 The performance of vaginal pH testing for bacterial vaginosis improved by increasing the cutoff to

223 eat pH and the accurate at-home diagnosis of bacterial vaginosis, improving the capabilities of curre

224 ted outcomes from treatment for asymptomatic bacterial vaginosis in a general obstetric population bu

225 hing has been reported to be associated with bacterial vaginosis in observational studies.

226 to prevent preterm birth by the treatment of bacterial vaginosis in pregnancy are disappointing.

227 ghed the benefits and harms of screening for bacterial vaginosis in pregnancy by identifying new evid

228 rce (USPSTF) recommendation on screening for bacterial vaginosis in pregnancy.

229 lance of benefits and harms of screening for bacterial vaginosis in pregnant persons at increased ris

230 te certainty that screening for asymptomatic bacterial vaginosis in pregnant persons not at increased

231 The USPSTF recommends against screening for bacterial vaginosis in pregnant persons not at increased

232 lance of benefits and harms of screening for bacterial vaginosis in pregnant women at high risk for p

233 Do not screen for bacterial vaginosis in pregnant women at low risk for pr

234 The treatment of asymptomatic bacterial vaginosis in pregnant women does not reduce th

235 In clinical trials, the treatment of bacterial vaginosis in pregnant women who previously had

236 lis infection, vulvovaginal candidiasis, and bacterial vaginosis) in HIV-1-seropositive versus HIV-1-

237 smears to diagnose abnormal vaginal flora or bacterial vaginosis, in accordance with Nugent's criteri

238 cterial phylotypes and those associated with bacterial vaginosis, including Atopobium vaginae, were i

239 rial species were detected in the women with bacterial vaginosis, including several species with no c

240 Bacterial vaginosis increases the susceptibility to sexu

241 Bacterial vaginosis is a common condition associated wit

242 Bacterial vaginosis is a condition associated with adver

243 Bacterial vaginosis is a highly prevalent and poorly und

244 Bacterial vaginosis is a risk factor for preterm birth.

245 Persistent bacterial vaginosis is associated with several bacteria

246 Bacterial vaginosis is common and is caused by a disrupt

247 nd that vaginal lavage fluid from women with bacterial vaginosis is deficient in antimicrobial polype

248 Bacterial vaginosis is far more than a nuisance infectio

249 Bacterial vaginosis is the most common lower genital tra

250 Bacterial vaginosis is the most common vaginal condition

251 Bacterial vaginosis is the most common vaginal disorder

252 he loss of normal immunostimulatory flora in bacterial vaginosis is thus associated with a local defi

253 ho have sex only with men, or to women whose bacterial vaginosis is treated with oral antibiotics.

254 The etiology of bacterial vaginosis is unknown, and there are no long-te

255 Bacterial vaginosis leaves patients with undesirable vag

256 cheese" odor on examination is predictive of bacterial vaginosis (LR, 3.2 [95% CI, 2.1-4.7]) while la

257 n adverse outcomes; identifying and treating bacterial vaginosis may reduce its occurrence.

258 Bacterial vaginosis might increase HIV risk by eliciting

259 We investigated whether bacterial vaginosis modified the efficacy of oral PrEP.

260 For bacterial vaginosis (n=73), neither the shedding of HIV-

261 erial vaginosis and 10 from patients without bacterial vaginosis, none shared the same DNA fingerprin

262 Women (N = 40) with incident bacterial vaginosis (Nugent 7-10) had significantly lowe

263 tic device, the Osmetech Microbial Analyzer--Bacterial Vaginosis (OMA-BV), which determines a patient

264 2-22 weeks' gestation (mean 15.6 weeks)--for bacterial vaginosis or abnormal vaginal flora.

265 either before labor for risk factors such as bacterial vaginosis or during preterm labor have not con

266 without the need for concurrent testing for bacterial vaginosis or vaginal dysbiosis.

267 ptive usage (P=.008), and lower frequency of bacterial vaginosis (P<.001) and gonorrhea (P=.03).

268 o determine whether prevention or control of bacterial vaginosis, particularly approaches that rely n

269 al human beta-defensin-2 mRNA, but a typical bacterial vaginosis pathogen, Gardnerella vaginalis, had

270 The cause of bacterial vaginosis remains poorly understood despite nu

271 Bacterial vaginosis represents a unique upheaval of the

272 Bacterial vaginosis resolved in 657 of 845 women who had

273 digital-vaginal sex (P = .04) and increased bacterial vaginosis risk (odds ratio, 4.2; 95% confidenc

274 to estimate the causal effect of douching on bacterial vaginosis risk while controlling for this conf

275 of N-9 for 2 weeks reduced the likelihood of bacterial vaginosis (RR, 0.5; 95% CI, 0.3-1.0).

276 inalis sensitivity 60.4%, specificity 45.6%; bacterial vaginosis sensitivity 61.6%, specificity 46.0%

277 %), high sensitivity but low specificity for bacterial vaginosis (sensitivity 95.2%, specificity 41.2

278 efficacy among subgroups of women defined by bacterial vaginosis status based on yearly microscopy an

279 eria gonorrhoeae, Trichomonas vaginalis, and bacterial vaginosis testing were collected from female a

280 gnificantly lower incidence of recurrence of bacterial vaginosis than placebo at 12 weeks.

281 potential nonantibiotic adjunct to existing bacterial vaginosis therapies in order to decrease the r

282 or helpful, and to explore the relevance of bacterial vaginosis to other adverse pregnancy outcomes,

283 eatment guidelines for gonorrhea, chlamydia, bacterial vaginosis, trichomonas, vulvovaginal candidias

284 Each diagnostic accuracy study for bacterial vaginosis, trichomoniasis, and genital herpes

285 0.72-0.87]) and lack of perceived odor makes bacterial vaginosis unlikely (LR, 0.07 [95% CI, 0.01-0.5

286 is and Neisseria gonorrhoeae using NAATs and bacterial vaginosis using Gram stains.

287 All participants had point-of-care tests for bacterial vaginosis (vaginal pH of 5.0 or above) and Tri

288 Accuracy of screening tests for bacterial vaginosis varies.

289 d for follow-up, the incidence of persistent bacterial vaginosis was 26% and was statistically signif

290 Bacterial vaginosis was assessed by Nugent score (Nugent

291 Bacterial vaginosis was associated with fewer episodes o

292 Bacterial vaginosis was based on a Nugent's Gram stain s

293 Bacterial vaginosis was strongly associated with M. homi

294 Bacterial vaginosis was treated with intravaginal metron

295 Using vaginal samples from women with bacterial vaginosis, we sequenced 16S genes using the V1

296 res categorized as normal, intermediate, and bacterial vaginosis were included.

297 endometrium, or vagina (including women with bacterial vaginosis), were obtained from BEI and ATCC re

298 nsmission is integral to the pathogenesis of bacterial vaginosis, which has substantial implications

299 d a retrospective analysis of 947 women with bacterial vaginosis who were enrolled in prospective stu

300 t of asymptomatic abnormal vaginal flora and bacterial vaginosis with oral clindamycin early in the s